Your Location：Home>News Center >> Industry news >> Review Supports Testosterone for Low Sexual Desire in Women

Review Supports Testosterone for Low Sexual Desire in Women

FRIDAY, July 26, 2019 -- For postmenopausal women with low sexual desire causing distress, testosterone is an effective treatment, with a preference for nonoral administration, according to a review published online July 25 in the The Lancet Diabetes & Endocrinology.

Rakibul M. Islam, Ph.D., from Monash University in Melbourne, Australia, and colleagues conducted a systematic review of the literature to assess potential benefits and risks of testosterone for women. Data were included from 46 reports of 36 randomized controlled trials with 8,480 participants.

The researchers found that compared with placebo or a comparator, testosterone significantly increased sexual function, including satisfactory sexual event frequency (mean difference, 0.85; 95 percent confidence interval [CI], 0.52 to 1.18), sexual desire (standardized mean difference, 0.36; 95 percent CI, 0.22 to 0.50), pleasure (mean difference, 6.86; 95 percent CI, 5.19 to 8.52), arousal (standardized mean difference, 0.28; 95 percent CI, 0.21 to 0.35), orgasm (standardized mean difference, 0.25; 95 percent CI, 0.18 to 0.32), responsiveness (standardized mean difference, 0.28; 95 percent CI, 0.21 to 0.35), and self-image (mean difference, 5.64; 95 percent CI, 4.03 to 7.26); reductions were seen in sexual concerns (mean difference, 8.99; 95 percent CI, 6.90 to 11.08) and distress (standardized mean difference, −0.27; 95 percent CI, −0.36 to −0.17) in postmenopausal women. When testosterone was administered orally, but not when administered nonorally, there was a significant increase in low-density lipoprotein cholesterol, and reductions in total cholesterol, high-density lipoprotein cholesterol, and triglycerides. There was an overall increase in weight with testosterone treatment; no effect was reported on body composition, musculoskeletal variables, or cognitive measures.

"Our comprehensive systematic review provides robust support for a trial of testosterone treatment, using a dose appropriate for women, when clinically indicated in postmenopausal women," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Hits：【Print】

Pre：FDA Approves Baqsimi FDA Approves Baqsimi (glucagon) Nasal Powder for the Treatment of Severe Hypoglycemia Next：FDA Approves Nubeqa FDA Approves Nubeqa (darolutamide) for Men with Non-Metastatic Castration-Resistant Prostate Cancer